Aplidin - Dexamethasone in Relapsed/Refractory Myeloma (ADMYRE)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
PharmaMar
ClinicalTrials.gov Identifier:
NCT01102426
First received: March 31, 2010
Last updated: June 11, 2015
Last verified: June 2015
  Purpose

Study of Plitidepsin in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma.


Condition Intervention Phase
Relapsed/Refractory Multiple Myeloma
Drug: plitidepsin + dexamethasone
Drug: dexamethasone
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma

Resource links provided by NLM:


Further study details as provided by PharmaMar:

Primary Outcome Measures:
  • Progression Free Survival (PFS) as per intention-to-treat (ITT) [ Time Frame: Estimated average: 5 months. From randomization to the first evidence of progressive disease or death due to any cause ] [ Designated as safety issue: No ]
    To compare the efficacy of plitidepsin in combination with dexamethasone vs. dexamethasone alone as measured by progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (MM).


Secondary Outcome Measures:
  • Response rate [ Time Frame: Every 4 weeks untill progression ] [ Designated as safety issue: No ]
  • Duration of Response [ Time Frame: Estimated average: 3 months. From the date of first documentation of response to the date of disease progression or death. ] [ Designated as safety issue: No ]
  • Overall Survival [ Time Frame: Estimated average: 9 months. From randomization to the first evidence of progressive disease or death due to any cause ] [ Designated as safety issue: No ]
    Overal Survival (OS) is defined as the time from the date of randomization to the date of death or last contact


Estimated Enrollment: 250
Study Start Date: June 2010
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A
plitidepsin + dexamethasone combination
Drug: plitidepsin + dexamethasone
plitidepsin: powder and solvent for concentrate for solution for infusion. 2 mg vial + 4 ml ampoule. 5 mg/m2 intravenously (i.v.) over three hours on Day 1 and 15 every 4 weeks. dexamethasone: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks at least one hour before plitidepsin infusion.
Other Name: APLIDIN (plitidepsin)
Active Comparator: Arm B
dexamethasone single agent
Drug: dexamethasone
4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.

Detailed Description:

Phase III Study in Patients with Relapsed/Refractory Multiple Myeloma to compare the efficacy of plitidepsin in combination with dexamethasone vs. dexamethasone alone measured by progression-free survival (PFS) and to evaluate tumor response, duration of response (DR), overall survival (OS) and to rule out any effect of plitidepsin on the duration of the QT/QTc interval (time corresponding to the beginning of depolarization to re-polarization of the ventricles).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2
  • Life expectancy ≥ 3 months.
  • Patients previously diagnosed with multiple myeloma
  • Patients must have relapsed or relapsed and refractory multiple myeloma (MM) after at least three but not more than six prior therapeutic regimens for MM, including induction therapy and stem cell transplant in candidate patients, which will be considered as only one regimen.
  • Patients must have received previous bortezomib-containing and lenalidomide-containing regimens (or thalidomide where lenalidomide is not available)
  • Women must have a negative serum pregnancy test
  • Voluntarily signed and dated written informed consent

Exclusion Criteria:

  • Concomitant diseases/conditions
  • Women who are pregnant or breast feeding.
  • Concomitant medications that include corticosteroids, chemotherapy, or other therapy that is or may be active against MM
  • Known hypersensitivity to any involved study drug or any of its formulation components
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01102426

  Hide Study Locations
Locations
United States, Alabama
1107
Tuscaloosa, Alabama, United States
United States, California
1103
Los Angeles, California, United States
United States, Florida
1105
Jacksonville, Florida, United States
United States, New York
1102
New York, New York, United States
United States, Ohio
1104
Canton, Ohio, United States
Australia
108
Adelaide, Australia
102
Canberra, Australia
101
Geelong, Australia
105
Parkville, Australia
106
Perth, Australia
104
South Brisbane, Australia
109
Woodvillle, Australia
Austria
202
Graz, Austria
204
Innsbruck, Austria
203
Salzburg, Austria
201
Wien, Austria
205
Wien, Austria
208
Wien, Austria
Belgium
304
Brugge, Belgium
303
Brussels, Belgium
301
Brussels, Belgium
302
Gent, Belgium
Czech Republic
502
Brno, Czech Republic
503
Hradec Kralove, Czech Republic
501
Praha, Czech Republic
France
601
Lille, France
602
Nantes, France
606
Rouen, France
604
Vandoeuvre, France
Germany
709
Düsseldorf, Germany
705
Essen, Germany
706
Frankfurt, Germany
707
Frankfurt, Germany
708
Freiburg, Germany
703
Heidelberg, Germany
702
Munchen, Germany
704
Würzburg, Germany
Greece
1301
Athens, Greece
1303
Patras, Greece
1302
Thessaloniki, Greece
Ireland
1401
Dublin, Ireland
Italy
806
Bari, Italy
801
Genova, Italy
805
Reggio Emilia, Italy
803
Rozzano, Italy
804
San Giovanni Rotondo, Italy
802
Torino, Italy
Korea, Republic of
1502
Anyang, Korea, Republic of
1501
Daejeon, Korea, Republic of
1507
Hwasun, Korea, Republic of
1506
Incheon, Korea, Republic of
1505
Jeonju, Korea, Republic of
1508
Seongnam, Korea, Republic of
1503
Seoul, Korea, Republic of
1504
Seoul, Korea, Republic of
1509
Seoul, Korea, Republic of
Netherlands
901
Rotterdam, Netherlands
902
Rotterdam, Netherlands
New Zealand
1601
Christchurch, New Zealand
1602
Takapuna, Auckland, New Zealand
Poland
1704
Opole, Poland
1703
Warszawa, Poland
Portugal
1802
Braga, Portugal
1801
Porto, Portugal
Puerto Rico
2001
Hato Rey, Puerto Rico
Spain
1201
Barcelona, Spain
1203
Barcelona, Spain
1209
Barcelona, Spain
1210
Madrid, Spain
1207
Madrid, Spain
1206
Murcia, Spain
1204
Palma de Mallorca, Spain
1208
Salamanca, Spain
1202
San Sebastián, Spain
1205
Valencia, Spain
Taiwan
1901
Putz city, Taiwan
1902
Taipei, Taiwan
1903
Taipei, Taiwan
United Kingdom
1003
Bournemouth, United Kingdom
1004
Bradford, United Kingdom
1001
London, United Kingdom
1002
London, United Kingdom
1005
Nottingham, United Kingdom
Sponsors and Collaborators
PharmaMar
Investigators
Principal Investigator: Óscar F. Ballester, M.D. Edwards Comprehensive Cancer Center, Marshall University (Huntington)
Principal Investigator: Rubén Niesvizky, M.D. NY Presbyterian Hosp. - Cornell University - NY
  More Information

No publications provided

Responsible Party: PharmaMar
ClinicalTrials.gov Identifier: NCT01102426     History of Changes
Other Study ID Numbers: APL-C-001-09
Study First Received: March 31, 2010
Last Updated: June 11, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by PharmaMar:
Multiple Myeloma
Aplidin
plitidepsin
dexamethasone

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Paraproteinemias
Vascular Diseases
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Anti-Inflammatory Agents
Antiemetics
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Central Nervous System Agents
Enzyme Inhibitors
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 30, 2015